Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin pharmacokinetics in patients with augmented renal clearance
IRCT20180802040665N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Apr 2021
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vancomycin in augmented renal clearance (ARC), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Vancomycin pharmacokinetic parameters. Started Apr 2021; status: completed.
02
Drugs
vancomycin
03
Conditions
augmented renal clearance (ARC)
Beyond the preview
Go deeper on IRCT20180802040665N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180802040665N1.